Episode Details

Amneal Pharmaceuticals stock is currently at $12.64, mirroring the broader markets performance. Over the past six months, its gained 6.2%, lagging the S&P 500s 7.9% increase. Analysts predict a modest 2.4% revenue growth in the next year, a significant slowdown from the past five-year average of 8.7%. The companys 4.9% average return on invested capital also falls short of the healthcare sectors cost of capital. Despite trading at a reasonable 13.3 times forward earnings, experts remain unconvinced about its buy potential. With stronger opportunities in software and edge computing, Amneal may not be a worthwhile addition to your portfolio.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/5604bcf75617e47c